News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,911 Results
Type
Article (40018)
Company Profile (250)
Press Release (664642)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204283)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81141)
Employer Resources (172)
FDA (16249)
Job Trends (14887)
News (345508)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1444)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2868)
Cardiovascular disease (213)
Career advice (1682)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66859)
Collaboration (1014)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2624)
CRISPR (56)
C-suite (328)
Cystic fibrosis (112)
Data (3002)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6424)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (126)
Earnings (87455)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113746)
Executive appointments (845)
FDA (17902)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (374)
GLP-1 (783)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (8)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (19)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (90)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19582)
Metabolic disorders (849)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2120)
NextGen: Class of 2025 (6518)
Non-profit (4488)
Now hiring (47)
Obesity (428)
Opinion (218)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (299)
Patient recruitment (166)
Peanut (50)
People (57692)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29449)
Phase III (21920)
Pipeline (1637)
Policy (200)
Postmarket research (2563)
Preclinical (8871)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (458)
Real estate (5917)
Recruiting (66)
Regulatory (22637)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3589)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (91)
Last 7 days (350)
Last 30 days (1885)
Last 365 days (31244)
2025 (16802)
2024 (35221)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46540)
2018 (35018)
2017 (32109)
2016 (31481)
2015 (37552)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38212)
Australia (6232)
California (7441)
Canada (2360)
China (671)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82111)
Florida (1118)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (637)
India (27)
Indiana (361)
Iowa (16)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1023)
Massachusetts (5529)
Michigan (246)
Minnesota (450)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2080)
New Mexico (28)
New York (2085)
North Carolina (1080)
North Dakota (8)
Northern California (3277)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1612)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2784)
Tennessee (126)
Texas (1126)
United States (27576)
Utah (220)
Virginia (185)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
704,911 Results for "annexon inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy
Jefferies analysts predict Annexon’s tanruprubart could be approved by mid-2026.
April 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
May 29, 2025
·
1 min read
Press Releases
Annexon Reports Inducement Grants to 2 New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
·
1 min read
Press Releases
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 12, 2025
·
12 min read
Press Releases
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
May 8, 2025
·
9 min read
Press Releases
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
June 19, 2025
·
8 min read
Press Releases
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
May 12, 2025
·
6 min read
Press Releases
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
May 20, 2025
·
8 min read
Drug Development
Annexon’s Pivotal Phase III GBS Trial Hits Goal, Tees Up Approval Filing
Annexon’s late-stage Guillain-Barré syndrome trial has hit its primary endpoint and laid the foundation for a filing for approval next year, the company said Tuesday.
June 4, 2024
·
2 min read
·
Nick Paul Taylor
Press Releases
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2025
April 17, 2025
·
1 min read
1 of 70,492
Next
